Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 5,280,000 shares, a drop of 14.6% from the October 15th total of 6,180,000 shares. Based on an average trading volume of 2,990,000 shares, the short-interest ratio is currently 1.8 days.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CAPR. Cantor Fitzgerald boosted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday. Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an "overweight" rating and a $35.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday. Oppenheimer reissued an "outperform" rating and set a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, Maxim Group boosted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday, September 25th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded up $0.12 during midday trading on Friday, hitting $18.61. 929,811 shares of the company traded hands, compared to its average volume of 1,147,541. The firm has a market cap of $845.08 million, a P/E ratio of -17.56 and a beta of 4.00. The stock has a 50-day moving average price of $15.21 and a 200 day moving average price of $8.48. Capricor Therapeutics has a 12-month low of $2.87 and a 12-month high of $23.40.

Insider Buying and Selling at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm's stock in a transaction on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 12.00% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after buying an additional 200,499 shares during the last quarter. State Street Corp boosted its stake in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after acquiring an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Capricor Therapeutics during the third quarter valued at about $3,806,000. PFM Health Sciences LP bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $2,324,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.